vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and NSTS Bancorp, Inc. (NSTS). Click either name above to swap in a different company.
Citius Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($3.9M vs $2.5M, roughly 1.6× NSTS Bancorp, Inc.). NSTS Bancorp, Inc. runs the higher net margin — 214.3% vs -238.2%, a 452.5% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
NSTS Bancorp, Inc. is a U.S.-based bank holding company. It offers a comprehensive suite of retail and commercial banking products and services, including deposit accounts, personal loans, commercial loans, and wealth management solutions, primarily serving individual consumers and small-to-medium enterprises in its regional operating areas.
CTXR vs NSTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $2.5M |
| Net Profit | $-9.4M | $135.0K |
| Gross Margin | 80.0% | — |
| Operating Margin | -228.7% | — |
| Net Margin | -238.2% | 214.3% |
| Revenue YoY | — | 3.0% |
| Net Profit YoY | 8.6% | 393.5% |
| EPS (diluted) | $-0.38 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $2.5M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $2.5M | ||
| Q1 25 | — | $2.2M | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $2.3M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | $-9.4M | $135.0K | ||
| Q3 25 | — | $65.0K | ||
| Q2 25 | — | $-258.0K | ||
| Q1 25 | — | $-328.0K | ||
| Q4 24 | — | $-46.0K | ||
| Q3 24 | — | $-171.0K | ||
| Q2 24 | — | $-326.0K | ||
| Q1 24 | — | $-246.0K |
| Q4 25 | 80.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -228.7% | — | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | -10.1% | ||
| Q1 25 | — | -15.2% | ||
| Q4 24 | — | -71.9% | ||
| Q3 24 | — | -7.6% | ||
| Q2 24 | — | -14.2% | ||
| Q1 24 | — | -12.2% |
| Q4 25 | -238.2% | 214.3% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | -10.1% | ||
| Q1 25 | — | -15.2% | ||
| Q4 24 | — | -71.9% | ||
| Q3 24 | — | -7.6% | ||
| Q2 24 | — | -14.2% | ||
| Q1 24 | — | -12.2% |
| Q4 25 | $-0.38 | — | ||
| Q3 25 | — | $0.01 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.03 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $34.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $80.0M |
| Total Assets | $140.4M | $266.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | $34.0M | ||
| Q3 25 | — | $34.1M | ||
| Q2 25 | — | $47.5M | ||
| Q1 25 | — | $57.5M | ||
| Q4 24 | — | $53.5M | ||
| Q3 24 | — | $34.6M | ||
| Q2 24 | — | $32.4M | ||
| Q1 24 | — | $36.4M |
| Q4 25 | $80.0M | $80.0M | ||
| Q3 25 | — | $78.9M | ||
| Q2 25 | — | $77.8M | ||
| Q1 25 | — | $77.5M | ||
| Q4 24 | — | $76.5M | ||
| Q3 24 | — | $78.4M | ||
| Q2 24 | — | $76.5M | ||
| Q1 24 | — | $77.0M |
| Q4 25 | $140.4M | $266.6M | ||
| Q3 25 | — | $269.8M | ||
| Q2 25 | — | $276.0M | ||
| Q1 25 | — | $282.7M | ||
| Q4 24 | — | $278.7M | ||
| Q3 24 | — | $268.4M | ||
| Q2 24 | — | $265.9M | ||
| Q1 24 | — | $265.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $4.1M |
| Free Cash FlowOCF − Capex | — | $3.9M |
| FCF MarginFCF / Revenue | — | 156.9% |
| Capex IntensityCapex / Revenue | — | 4.1% |
| Cash ConversionOCF / Net Profit | — | 30.01× |
| TTM Free Cash FlowTrailing 4 quarters | — | $4.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | $4.1M | ||
| Q3 25 | — | $2.9M | ||
| Q2 25 | — | $655.0K | ||
| Q1 25 | — | $-2.7M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $92.0K |
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | $2.9M | ||
| Q2 25 | — | $616.0K | ||
| Q1 25 | — | $-2.7M | ||
| Q4 24 | — | $9.1M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | — | $-1.7M | ||
| Q1 24 | — | $76.0K |
| Q4 25 | — | 156.9% | ||
| Q3 25 | — | 113.9% | ||
| Q2 25 | — | 24.2% | ||
| Q1 25 | — | -126.1% | ||
| Q4 24 | — | 373.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | -76.4% | ||
| Q1 24 | — | 3.8% |
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | 13.1% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | — | 5.1% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | — | 30.01× | ||
| Q3 25 | — | 44.03× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
